How to Enter the Japan and South Korea Medical Device Markets
A regional entry playbook for Japan and South Korea: the shared local-holder structure (Japan MAH/D-MAH, Korea KLH), how FDA/CE/MDSAP evidence is actually leveraged in each, a decision framework for which market to enter first by product type, and a two-country delta table.
Regional verdict
Japan and South Korea share the same structural shape: neither regulator will deal with a foreign manufacturer directly — both require a designated Japan/Korea-based party to sit between the manufacturer and the regulator. But the two markets diverge sharply on who actually owns the certificate once it is issued. Korea's Korea License Holder (KLH) always owns the Import Item License in its own name; the foreign manufacturer cannot register or hold it directly under any structure. Japan's standard route works the same way — a Marketing Authorization Holder (MAH) owns the Shonin/Ninsho certificate — but Japan additionally offers a second route unavailable in Korea: under Foreign Special Approval, a foreign manufacturer of a Class II, III, or IV device can retain ownership of the certificate itself and appoint a Designated MAH (D-MAH) purely as its in-country regulatory agent. Both are mature, high-evidence, high-reward markets — MFDS and PMDA/MHLW rank among the world's most technically rigorous regulators — with realistic timelines spanning from under a month for the lowest-risk notification form to 24-36 months for the highest-risk full approval, and reimbursement listing (HIRA in Korea, Chuikyo/NHI listing in Japan) sitting as a separate, parallel gate after regulatory approval in both countries.
Standard pathway flow
The standard flow has the same five-step shape in both markets, with two branch points: the risk-based review track at step 4, and — uniquely in Japan — a certificate-ownership fork at step 2.
1. Classify and prepare the dossier
Confirm the local risk class — Korea Class I–IV (Medical Devices Act) or Japan Class I–IV (PMD Act) — and identify the branch-defining fact for Class II/III: in Korea, whether a substantial-equivalent (S.E.) predicate already exists; in Japan, whether MHLW has published a Certification Standard (認証基準) for the specific product category. Build the technical dossier in IMDRF STED-aligned format, which both MFDS and PMDA/RCB dossiers share structurally with CE and FDA files.
2. Appoint the local holder — and, in Japan, decide who owns the certificate
Appoint the Korea License Holder (KLH) in Korea — always the legal owner of the Import Item License, whether an own subsidiary, a distributor, or an independent third-party KLH firm. In Japan, decide between the standard route (a Japan-based Marketing Authorization Holder, MAH, that owns the Shonin/Ninsho certificate — again a subsidiary or a distributor) and, for Class II–IV devices only, the Foreign Special Approval route, where the foreign manufacturer itself retains the certificate and appoints a Designated MAH (D-MAH) purely as its in-country agent.
3. Submit through the holder/agent to the regulator
The KLH files with MFDS directly, or through one of six MFDS-designated third-party certification reviewers for predicate-backed Class II (and select Class III) devices. In Japan, the MAH or D-MAH files a Todokede with the prefectural government (Class I), a Ninsho application with a Registered Certification Body (RCB, for Certification-Standard-eligible Class II/III), or a Shonin application reviewed by PMDA with final approval issued by MHLW.
4. Review — branches by risk, plus the QMS/MDSAP layer
Low-risk products clear quickly with little substantive review — Korea Class I notification in roughly 1–2 weeks, Japan Class I Todokede in under a month. Mid-risk products with a fast track move faster still — Korea Class II certification (with predicate) in about 3–6 months, Japan Ninsho in about 4–12 months. High-risk products go through full technical review — Korea Class II/III/IV approval (허가) runs 8–24 months, Japan Class II/III/IV Shonin runs 15–36 months depending on class. In parallel, both regulators assess QMS conformity: MFDS accepts ISO 13485 issued by an MDSAP-recognized certification body as KGMP-equivalent evidence, while PMDA — one of MDSAP's five founding participating authorities — has directly accepted MDSAP audit reports as QMS Ordinance No. 169 conformity evidence since 2016, the more institutionally established of the two MDSAP-leverage mechanisms.
5. Licence issuance, post-market duties, and the reimbursement gate
Once issued, both the Korean Import Item License and the Japanese Shonin/Ninsho certificate carry no fixed expiry, but each sits on a periodic renewal clock underneath it — Korea's KGMP certificate every 3 years and post-market re-evaluation roughly every 5 years; Japan's QMS conformity commonly re-confirmed on a 3–5 year cycle. Post-market vigilance, recalls, and change-management duties sit with the KLH in Korea and the MAH/D-MAH in Japan, not the foreign manufacturer directly. In both countries, reimbursement listing — HIRA in Korea, Chuikyo-run NHI listing in Japan — is a separate application that typically adds another 6–12+ months before the device can generate meaningful hospital-channel revenue.
License-holder arrangements
Both countries mandate an in-country party, but the three shared structural choices carry a different meaning in each — and Japan adds a fourth option Korea does not have at all.
Own subsidiary as holder
In Korea, the manufacturer's own Korean-incorporated entity becomes the KLH and owns the Import Item License outright — full control, but the entity must also hold its own Import Business License before product registration can begin. In Japan, an own Japanese subsidiary becomes the MAH and owns the Shonin/Ninsho certificate the same way. Both are the slowest to stand up and the highest-cost option, but preserve full registration and renewal control independent of any distributor relationship.
Distributor as holder
The fastest, lowest-cost way to launch in both countries, since the distributor already holds its own import licence or MAH licence. The trade-off is the same in both: the certificate sits in the distributor's name, so if the relationship ends, Korea requires a formal KLH-change filing or a fresh registration citing S.E. to the existing product, and Japan requires a partial-change approval application (承認事項一部変更) — both procedurally burdensome, and neither guarantees uninterrupted supply during the transition.
Independent third-party holder — Korea's KLH service vs. Japan's D-MAH
This is where the two countries diverge most. In Korea, an independent third-party KLH firm holds the registration separately from commercial distribution — the manufacturer can appoint or replace distributors without re-filing, but the KLH, not the manufacturer, still legally owns the certificate. In Japan, the Foreign Special Approval scheme (Class II–IV only) goes further: the foreign manufacturer itself owns the certificate, and a Designated MAH (D-MAH) acts purely as its in-country regulatory agent, filing on the manufacturer’s own signature. Switching a D-MAH is an administrative agent change, not a certificate transfer, and does not require a departing partner’s cooperation — a structurally cleaner exit than anything Korea’s KLH system offers.
Japan's Foreign Special Approval / D-MAH route is the one structural option this entire market-pair analysis turns on: for Class II, III, and IV devices, a foreign manufacturer can keep the certificate in its own name without incorporating in Japan at all — appointing a D-MAH purely as a regulatory agent rather than surrendering ownership to a local party. Korea has no equivalent; every KLH mode in Korea, including the independent third-party option, still places legal ownership of the licence with the KLH, not the manufacturer. Class I devices in Japan cannot use the D-MAH route and must go through a standard Japan-based MAH under Todokede, the same structural position as Korea's Class I notification.
Reference-certificate leverage
- FDA and CE are recognized in some form by both MFDS and PMDA/MHLW; NMPA (China) carries essentially no formal or informal weight with either regulator.
- Korea's Abbreviated Review (약식심사) is the more mechanical of the two mechanisms: for product categories explicitly within its scope, an application backed by FDA 510(k) clearance or PMA approval can bypass detailed technical-document review in favor of a recognition-based assessment, compressing a 12–18 month standard review toward roughly 4–8 months — eligibility must be confirmed category-by-category via MFDS's 사전검토 pre-review consultation system.
- Japan offers no equivalent formal fast lane for FDA/CE data: FDA 510(k) Summaries and PMA clinical data are broadly reused as supporting technical evidence in PMDA review and are cited as a supporting (not codified) factor in SAKIGAKE eligibility discussions and MAH/D-MAH recruitment, while CE MDR technical files are directly reusable for document preparation because both frameworks trace to the same IMDRF STED structure — but neither certificate compresses PMDA's statutory review clock the way Korea's Abbreviated Review does.
- Japan's biggest FDA/CE caveat is ethnic sensitivity: PMDA can still request supplementary Japanese-population bridging data even when a device already holds both FDA PMA and EU MDR CE approval, if the existing evidence lacks an adequate East Asian patient subset — this is the single most common reason a manufacturer's Japan timeline built around ‘we already have FDA/CE’ turns out to be wrong. Korea's comparable concern is more narrowly codified around IVD bridging evidence specifically, not a general ethnic-sensitivity gate across all device types.
- MDSAP carries more institutionally established weight in Japan than in Korea: Japan is one of MDSAP's five founding participating authorities (with the US FDA, Health Canada, Australia's TGA, and Brazil's ANVISA), and PMDA has directly accepted MDSAP audit reports as QMS Ordinance No. 169 conformity evidence since 2016, avoiding a dedicated PMDA on-site inspection. Korea is not an MDSAP founding authority; MFDS instead accepts an ISO 13485 certificate issued by an MDSAP-recognized certification body as KGMP-equivalent evidence — a related but narrower mechanism than Japan's direct MDSAP-report acceptance.
Suggested entry sequence
Korea is the more common default first stop for a standard Class II/III hardware device that already has both FDA/CE approval and an identifiable Korean predicate: Abbreviated Review can compress the standard 12–18 month timeline to roughly 4–8 months, KLH setup in distributor mode is faster and cheaper than incorporating in Japan, and a completed MFDS registration is a useful reference data point going into a subsequent Japan filing. This ordering flips when the product is genuinely first-in-world or first-in-Japan innovative with no Korean predicate available — see the Japan entry below.
Japan can legitimately go first in two scenarios: (1) the product falls under a published Japan Certification Standard with no Korean predicate available, since Ninsho (4–12 months, RCB-reviewed) can then outpace Korea's predicate-less approval track (8–15 months); or (2) the product is genuinely novel and eligible for SAKIGAKE priority designation (6-month target) or the Conditional Approval System, both of which require Japan-first or Japan-simultaneous filing intent as an eligibility condition — filing Japan second after Korea can forfeit SAKIGAKE eligibility entirely. For SaMD/digital-health products specifically, weigh Japan's DASH for SaMD two-step approval option against Korea's Digital Medical Products Act (DMPA, fully effective January 24, 2026), which now gives digital medical products their own dedicated review and labelling track separate from hardware devices.
Country-by-country delta table
| Country | Regulator | Registration form | Licence holder mode | Validity | Key special requirement |
|---|---|---|---|---|---|
| South Korea | MFDS (Ministry of Food and Drug Safety) | Notification (신고) / Certification (인증) / Approval (허가), Class I–IV | Mode B — mandatory Korea License Holder (KLH); foreign manufacturer cannot register or hold the licence directly under any structure | Import Item License has no fixed expiry; periodic post-market re-evaluation roughly every 5 years; KGMP certificate valid 3 years | 14-element Korean-language labelling (MFDS Notice 2022-110); Abbreviated Review (약식심사) available for defined FDA 510(k)/PMA categories; local type testing required for implantable, life-supporting, or genuinely novel devices |
| Japan | PMDA (technical review) + MHLW (final approval) | Todokede (届出) / Ninsho (認証) / Shonin (承認), Class I–IV | Standard route — mandatory Japan-based MAH owns the certificate; alternative — Foreign Special Approval lets the foreign manufacturer retain ownership via a Designated MAH (D-MAH), Class II–IV only, not available for Class I | Shonin/Ninsho certification has no fixed expiry; QMS conformity commonly re-confirmed on a 3–5 year cycle | Japanese-language label and electronic package insert (添付文書, mandatory electronic format for professional-use devices since August 2021); PMDA has accepted MDSAP audit reports as QMS evidence since 2016 (Japan is a founding MDSAP authority); ethnic-sensitivity bridging data can still be requested despite existing FDA/CE approval |
Common pitfalls
- Conflating certificate ownership with commercial partnership: defaulting to a distributor-affiliated KLH or MAH without weighing the alternatives is the most common structuring mistake in both countries — Korea's independent third-party KLH and Japan's D-MAH (Class II–IV) both exist specifically to decouple the two roles, and the contract should fix certificate-transfer/termination terms before signing, not after a dispute.
- Treating Korean and Japanese labelling as a late-stage translation task: Korea's 14-element label requirement (MFDS Notice 2022-110) and Japan's package-insert content set both require country-specific mandatory content and approved phrasing, not a straight translation of a CE/FDA label, and commonly need 6-8+ weeks of lead time — poor-quality translation is a frequently cited trigger for deficiency-notice or query rounds.
- Assuming FDA/CE approval automatically shortens the Japan timeline the way it does in Korea: Japan's acceleration levers (SAKIGAKE, Conditional Approval, MDSAP-report reliance) are narrower and criteria-specific, and PMDA's independent ethnic-sensitivity review can add a Japan-specific bridging-data request regardless of reference-market approval — budget for this possibility from the outset rather than discovering it mid-review.
- Sequencing reimbursement as an afterthought: MFDS/PMDA approval is a compliance gate, not a commercial one — HIRA reimbursement negotiation in Korea and Chuikyo-run NHI listing in Japan each typically take 6-12 months (longer for innovative/high-value devices), and should be planned in parallel with the regulatory dossier, not started only after the certificate is in hand.
Explore the country pages
Each row links to the full country regulatory report for registration pathway, timeline, cost, and post-market obligations.